AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound having a structure according to formula I



(I)

or ~~and~~ the pharmaceutically acceptable salts ~~salts, esters, and prodrug forms~~ thereof wherein

R^1 is ~~OMe or~~ R^2R^3N, where R^2 is H and R^3 is ~~are independently~~ H, allyl, or a substituted C_1-C_8 alkyl group substituted with a substituent selected from the group consisting of heteroaryl, aryl, halo, trifluoromethoxy, trifluoromethyl, hydroxy, alkoxy, cycloalkyloxy, heterocyclooxy, alkanoyl, alkanoyloxy, amino, alkylamino, quarternary ammonium, aralkylamino, cycloalkylamino, heterocycloamino, dialkylamino, alkanoylamino, thio, alkylthio, cycloalkylthio, heterocyclothio, ureido, nitro, cyano, carboxy, carboxylalkyl, carbamyl, alkoxycarbonyl, alkylthiono, arylthiono, alkylsulfonyl, sulfonamido, and aryloxy, ~~C_2-C_8 alkenyl, C_2-C_8 alkynyl, cycloalkyl, heterocyclo, aryl, or heteroaryl~~; or R^2 and R^3 and the nitrogen to which they are attached combine to form an azetidinyl ~~a substituted or unsubstituted 3, 4, 5, 6, or 7 membered~~ ring; and

R^4 is H; ~~or $CH_2C(=O)R^5$, where R^5 is a substituted or unsubstituted phenyl group.~~

wherein further

heteroaryl denotes a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic aryl ring system wherein each heteroaryl ring has 1, 2 or 3 heteroatoms

selected from N, O and S, where the N and S optionally may be oxidized and the N optionally may be quaternized;
cycloalkyl denotes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclododecyl, or adamantyl; and
heterocyclo denotes a 4 to 7 membered monocyclic, 7 to 11 membered bicyclic, or 10 to 15 membered tricyclic ring system having at least one heteroatom in at least one carbon atom-containing ring, wherein each heterocyclic ring has 1, 2 or 3 heteroatoms selected from N, O and S, where the N and S optionally may be oxidized and the N optionally may be quaternized.

2-3. (Canceled)

4. (Currently Amended) A compound according to claim 1 [[2]], wherein ~~R^1 is R^2R^3N, where R^2 is H and~~ R^3 is a substituted C_1-C_8 alkyl group.

5. (Original) A compound according to claim 4, wherein R^3 is a substituted C_2 alkyl group.

6. (Original) A compound according to claim 5, wherein the substituent is selected from the group consisting of fluoro, cycloalkylamino, dialkylamino, heterocyclo having at least one nitrogen ring atom, and heteroaryl having at least one nitrogen ring atom.

7. (Currently Amended) A compound according to claim 1 [[2]], wherein ~~R^1 is R^2R^3N, where R^2 is H and~~ R^3 is allyl.

8. (Original) A compound according to claim 1 [[2]], wherein ~~R^1 is R^2R^3N, where R^2 and~~ R^3 ~~are each~~ is H.

9. (Currently Amended) A compound according to claim 1 [[2]], wherein ~~R^1 is R^2R^3N, where~~ R^2 and R^3 and the nitrogen to which they are attached combine to form an azetidinyl ~~a substituted or unsubstituted 3, 4, 5, 6, or 7 membered~~ ring.

10. (Currently Amended) A compound according to claim 1 [[2]], wherein R^1 is selected from the group consisting of


,

,

,

,


,

,

,

,

and

.

11-16. (Canceled)

17. (Currently Amended) A method of inhibiting the proliferation of a target cell, comprising contacting a ~~the~~ target cell selected from the group consisting of a breast cancer, lung cancer, ovarian cancer, and leukemia cell with an effective amount of a compound having a structure according to claim 1.

18-19. (Canceled)

20. (Currently Amended) A method according to claim 17 ~~19~~, wherein the compound according to claim 1 has a structure according to formula I-b

(I-b)



21. (Currently Amended) A method according to claim 17 ~~19~~, wherein the compound according to claim 1 has a structure according to formula I-i

(I-i)



22. (Currently Amended) A method according to claim 17 ~~19~~, wherein the compound according to claim 1 has a structure according to formula I-j

(I-j)



23. (Currently Amended) A method of treating a hyperproliferative disease, comprising administering to a patient suffering from a ~~such~~ hyperproliferative disease selected from the group consisting of breast cancer, lung cancer, ovarian cancer, and leukemia a therapeutically effective amount of a compound according to claim 1.

24-25. (Canceled)

26. (Currently Amended) A method according to claim 23 ~~25~~, wherein the compound according to claim 1 has a structure according to formula I-b

(I-b)



27. (Currently Amended) A method according to claim 23 ~~25~~, wherein the compound according to claim 1 has a structure according to formula I-i

(I-i)



28. (Currently Amended) A method according to claim <u>23</u> ~~25~~, wherein the compound according to claim 1 has a structure according to formula I-j

(I-j)



29-34. (Canceled)